The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- Expert warns against charging phones while sleeping
- FCT NUJ pledges support for community policing in Abuja
- Jigawa launches agricultural support for 90,000 farmers
- CISLAC raises concerns over state policing constitutional amendment
- BOA introduces strict data-driven credit profiling for farmers
- ADP urges farmers to utilise extension services for higher yields
- NESREA uncovers illegal donkey slaughter abattoirs in Adamawa
- Former APWEN Chair, Eterigho, addresses global engineering conference
